WW

Wei Wu

Biotech Executive / Healthcare Investor

San Francisco Bay Area

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Senior Director, Venture Investments, JJDC

    2021

    JJDC is the strategic corporate venture capital group for Johnson & Johnson; launched in 1973, it is one of the longest-running and most reputable CVC in health care. I cover investments in areas of strategic interest to Johnson & Johnson. In support of J&J strategic objectives, I work closely with Innovation Centers, JLabs, Therapeutic Areas, Business Development, Commercial, and R&D Functional Areas.

  • Board Member

    2023

    Circode develops novel RNA therapeutics for multiple disease areas

  • Board Observer

    2022

    DAC Biotechnology is an antibody-drug-conjugate (ADC) company that has established an end-to-end capability for ADC generation and an innovative pipeline in pre-clinical and clinical stages.

2021 - 2021

  • Board Member

    2021 - 2021

    ImmPact Bio is pioneering a novel strategy to surmount a major challenge compromising current T-cell (CAR-T) therapy

  • Board Observer

    2020 - 2021

    Actym Therapeutics is developing a microbial-based immunotherapy platform for various challenging cancer types.

2019 - 2021

  • Senior Associate

    2019 - 2021

    Illumina Ventures is an independently managed fund focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, therapeutics, clinical diagnostics, and other opportunities to improve human health. My primary focus was on platform therapeutics related to genomics, synthetic biology, precision medicine, and new modalities. Covered investments: Actym Therapeutics, Kallyope, Encoded Therapeutics.

2019 - 2020

  • Advisory Board Member

    2019 - 2020

    Immunotherapies for cancer

  • Director, Healthcare Investment and Business Development

    2017 - 2019

    BOE Technology Group (https://www.boe.com/en/about/gsjs/), is a FORBES global2000 company headquartered in Beijing, China. BOE is a leader in semiconductor display technologies, products, manufacturing and services. BOE recently expands business into smart system and healthcare. BOE's healthcare investment focus on the intersection of high-tech and healthcare including: healthcare IoT, genomics, point-of-care diagnostics, medical device, consumer health, digital hospitals/care facilities, gene/cell therapy. BOE also seeks collaborations with investigators at universities/research institutes/hospitals through sponsored research to promote early-stage innovations in strategic interest areas. -Lead all aspects of sourcing and deal execution -Manage collaboration projects, investment portfolio, and LP-GP relationship -Recruitment, training, and team building -Corporate strategy, technology planning, and business development -PR/marketing/ecosystem expansion

2017 - 2019

  • Board Observer

    2017 - 2019

    Ceribell is focused on making EEG widely accessible, drastically more efficient, and more cost-effective to improve the diagnosis and treatment of neurological patients.

2017 - 2019

  • Board Observer

    2017 - 2019

    Baebies, guided by the vision that “everyone deserves a healthy start,” delivers innovative products and services for newborn screening and pediatric testing.